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Abstract 
 
Background: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide 
polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid 
pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS. 
 
Methods: We performed a meta-analysis of three cohort studies: PACMAN (n=357, age: 4-12 years, the 
Netherlands), BREATHE (n=820, age: 3-22 years, UK) and PAGES (n=391, age: 2-16 years, UK). 
Seventeen  Ggenes were selected based on a role in the glucocorticoid signaling pathway or a reported 
association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and 
oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three 
independent validation cohorts; the CAMP (clinical trial, n=172, age:5-12 years, USA), GALA II (n=745, 
age:8-21, USA) and PASS cohorts (n=391, age:5-18, UK) A fourth study population (CAMP, clinical 
trial, n=172, age: 5-12 years, USA) was included to test the robustness of the findings. Finally, all results 
were meta-analyzed.   
 
Results: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a 
nominal level with an increased risk of exacerbations in asthmatics despite corticosteroid treatmentusing 
ICS in the three cohorts studiesd. When CAMP was included in the meta-analysis the two SNPs remained 
associated with exacerbations. In a meta-analysis of the fourall six studies, ST13 rs138335 remainedwas 
associated with an increased risk of asthma-related hospital visits and OCS use in the previous year,; 
OR=1.282 per G allele for rs138335 (p=0.0213) and OR=1.2231 per G allele for rs138337 (p=0.0017) 
respectively.  and OCS usage in the previous year, OR= 1.30 per G allele for rs138335 (p=0.003) and 
OR=1.18 per G-allele for rs138337 (p=0.03).  
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Conclusion and clinical relevance: A novel susceptibility gene, ST13, coding for a co-chaperone of the 
glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite 
their ICS use. Genetic variation in the glucocorticoid signaling pathway may contribute to seems to add to 
the interindividual variability in clinical response to ICS treatment in children and young adults. 
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Abbreviations used 
BTS, British Thoracic Society; CAMP, Childhood Asthma Management Program; ED, Emergency 
Department; GALA II, Genes-environments & Admixture in Latino Americans; GC, glucocorticoid; GR, 
glucocorticoid receptor; ICS, Inhaled Corticosteroids; LABA, long-acting beta-2 agonist; LD, linkage 
disequilibrium; LTRA, leukotriene receptor antagonist; OCS, Oral Corticosteroids; PACMAN, 
Pharmacogenetics of Asthma Medication in Children: Medication with Anti-inflammatory effects; 
PAGES, Paediatric Asthma Gene Environment Study; SABA, short-acting beta agonist; SNP, Single 
Nucleotide Polymorphism; UPPER, Utrecht Pharmacy Practice Network for Education and Research.
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Introduction 
Inhaled corticosteroids (ICS) are considered first line therapy for reducing airway inflammation, 
improving lung function, and controlling asthma stability in patients with persistent asthma [1,2].  While 
most asthmatic patients have a beneficial response to inhaled corticosteroid therapy, approximately 10% 
of the patients suffer from severe symptoms despite regular use of corticosteroids [3], and almost half of 
the costs of asthma management arises from unscheduled health care visits due to exacerbations [4].
 
Heterogeneity in treatment response may partly be due to genetic variation [5]. An example of genetic 
variation in the FCER2 gene contributing to exacerbations despite ICS treatment has been published 
previously [6,7].   
 
Corticosteroids are thought to exert their anti-inflammatory effects primarily by binding to a ubiquitously 
expressed glucocorticoid receptor (GR) in the cytoplasm [8]. In the absence of glucocorticoids the 
receptor is predominantly sequestered in the cytoplasm in a multi-protein chaperone complex. Various 
chaperones and co-chaperones have been described to be involved in the stabilization and maturation of 
the receptor [9]. Upon binding of glucocorticoids to receptor, the complex translocates to the nucleus 
where it can block gene expression of a wide range of pro-inflammatory genes and promote the 
expression of anti-inflammatory genes. To date, there have been few studies addressing variations in 
corticosteroid receptor complex genes and steroid treatment response in patients with asthma [10,11]. 
 
We hypothesized that susceptibility genes might also be associated with an increased risk of 
exacerbations despite steroid treatment, due to a potential link with exacerbation-prone asthma 
phenotypes. In the present study we aim to relate genetic variations in genes in the steroid pathway and 
asthma susceptibility genes to asthma exacerbations despite ICS treatment. 
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Methods 
Study population  
Tag SNPs in 17 candidate genes were studied in three independent North-European cohorts of steroid-
treated asthmatic children and adolescents: 1) the Pharmacogenetics of Asthma Medication in Children: 
Medication with Anti-inflammatory effects (PACMAN) cohort study, 2) the BREATHE study and, 3) the 
Paediatric Asthma Gene Environment Study (PAGES).  For the current analyses we excluded participants 
of non-Northern European origin.  
 
PACMAN 
The PACMAN study is an observational cohort study of children (age: 4-12 years) with a reported 
(regular) use of asthma medication through community pharmacies in the Netherlands. Details of the 
study protocol have been described elsewhere [12]. We analyzed the PACMAN data obtained between 
2009 and 2012. Data were collected with the help of pharmacists belonging to the Utrecht Pharmacy 
Practice Network for Education and Research (UPPER), and the work was conducted in compliance with 
the requirements of the IRB of the Department of Pharmacoepidemiology and Clinical Pharmacology, 
Utrecht University. A detailed history of the subjects is obtained, including information on asthma 
symptoms, exacerbations and medication use over the preceding 12 months during a study visit in the 
community pharmacies. Saliva samples are collected for DNA extraction (Oragene DNA Self Collection 
kit, DNA Genotek, Inc., Ontaria, Canada). The Medical Ethics Committee of the University Medical 
Centre Utrecht has approved the PACMAN study.  
 
BREATHE 
The BREATHE study includes children and young adults (age: 3-22 years) with physician-diagnosed 
asthma through primary or secondary clinics in either Tayside or Dumfries (Scotland, United Kingdom)
 
[13,14]. We analyzed the BREATHE data obtained between 2004 and 2006. At the asthma clinic a 
detailed history was obtained, including information on symptoms, treatment and asthma exacerbations 
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over the preceding 6 months. Mouthwash samples were collected and DNA was isolated using Qiagen 
DNAeasy 96 kits (Qiagen GmbH, Hilden, Germany. The Tayside Committee on Medical Research Ethics 
has approved the BREATHE study.  
 
PAGES 
The PAGES study recruited children and adolescents (age: 2-16 years) with physician-diagnosed asthma 
through 15 secondary care asthma clinics across Scotland from 2008 to 2011. Details of the study 
protocol of the PAGES have been described elsewhere [15].  Briefly, a detailed history was obtained 
including information on symptoms, treatment and exacerbations over the preceding 6 months. Saliva 
samples were collected for DNA extraction (Oragene DNA Self Collection kit, DNA Genotek, Inc., 
Ontaria, Canada). The Plymouth and Cornwall Research Ethics Committee has approved the PAGES 
study.  
 
Validation cohorts 
First and second meta-analysis 
We performed two meta-analyses; in the first we included PACMAN, BREATHE and PAGES, according 
to the similarity in design (cohort) and uniformity in genotyping strategy (Sequenom platform, performed 
at Dundee University). In order to test the robustness of our findings, we assessed the identified 
significant associations of the first meta-analysis  in three additional independent populations: CAMP, the 
PASS cohort and GALA II and meta-analyzed the results.  a fourth population, the CAMP trial. This 
study differed in design (clinical trial) and genotyping strategy (imputation of GWAS data), and therefore 
was included in a second meta-analysis.   
 
CAMP trial  
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We studied 172 non-Hispanic white corticosteroid-treated children with asthma included in CAMP 
(USA). CAMP is a multi-center trial that randomized 1,041 children with mild-to-moderate asthma aged 
5 to 12 years to the ICS budesonide, nedocromil, or placebo twice daily. The participants were followed 
for a mean of 4.3 years and follow-up visits took place at 2 and 4 months after randomization and every 4 
months thereafter. The design of the study has been described previously [16]. We restricted our analysis 
to the non-Hispanic white subjects randomized to budesonide with available genotyping data (n=172).  
 
Pharmacogenetics of Adrenal Suppression (PASS) cohort 
PASS is a multicenter study of children with asthma (age 5-18 years), treated with corticosteroids, who 
required assessment of adrenal function with a Low Dose Short Synacthen Test (LDSST). Participants 
were recruited from November 2008 to September 2011 from 25 sites in the UK.  Eligibility criteria were 
as follows: treatment with ICS >6 months; diagnosis of asthma; under care of a pediatrician experienced 
in the treatment of asthma; clinical concern about adrenal suppression sufficient to warrant a 
LDSST. Study participants were recruited either prospectively (if LDSST not yet undertaken) or 
retrospectively (if LDSST already undertaken).  PASS received full ethical approval from Liverpool 
Paediatric Research Ethics Committee. 
 
Genes-Environment and Admixture in Latino Americans (GALA II) study 
The GALA II study is an ongoing multi-center study of Latino children and young adults with and 
without asthma, as described elsewhere [17]. Subjects were eligible if they were 8-21 years of age, self-
identified all four grandparents as Latino, and had <10 pack-years of smoking history. Asthma was 
defined based on physician diagnosis and report of symptoms and medication use within the last 2 years. 
For this study we only analyzed asthmatic children with a reported use of SABA and ICS in the past 12 
months. Patients included in this study were recruited from urban study centers across the mainland 
United States and Puerto Rico from 2008 to 2011. All patients completed a questionnaire with questions 
regarding their medical, asthma, medication use, allergic, social, environmental, and demographic 
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histories. In addition, all participants provided blood for genetic analysis.  Local institutional review 
boards approved the studies, and all subjects and legal guardians provided written informed 
assent/consent. 
 
Definition of ICS use 
Pharmacological management of asthma was categorized based on the British Thoracic Society (BTS) 
guidelines [2]:  step 0: no use of inhaled albuterol on demand in the past month, step 1: inhaled short-
acting beta-2 agonists (SABA) as needed, step 2: step 1 plus regular ICS, step 3: step 2 plus regular long-
acting inhaled beta-2 agonists (LABA) and, step 4: step 3 plus oral leukotriene receptor antagonists. For 
the present study we selected children and young adults on BTS treatment steps 2, 3 and 4.   
 
SNP selection and genotyping 
Ten genes were selected based on their involvement in the glucocorticoid (GC) receptor complex 
(NR3C1, HSPCA, HSPA4, FKBP4, ST13), GC transport (SERPINA6) or GC-mediated signalling 
(CREBBP, TBP, NCOA3, SMAD3). In addition, seven genes were selected based on a previously reported 
association with asthma susceptibility, severity or asthma medication response (ARG1, 17q21 locus, 
IL2RB IL18R1, PDE4D, HLA-DQ, BCL2) [178-1920]. We selected 50 tag SNPs. SNPs were included if 
the MAF > 0.2. Tag SNPs were selected using Tagger 
(http://www.broadinstitute.org/mpg/tagger/server.html) with a gene coverage threshold of 90%. 
Previously described SNPs in the genes of interest were also selected. Genotyping was performed using 
the Sequenom Mass Array platform (Sequenom, San Diego, California, USA). Genotype calls of all DNA 
samples and SNPs were examined for quality. Samples that consistently failed genotyping (≥ 20% of the 
SNPs) were excluded for further analyses. Subsequently, SNPs with a call rate < 95% were excluded, as 
well as SNPs not in Hardy-Weinberg equilibrium. A total of 38 SNPs (78%) in twelve genes passed this 
quality control (see  Supplementary Table 1 for selected genes and SNPs). The following genes did not 
pass quality control and were excluded from further analyses: HSPCA, HSPA4, IL18R1, HLA-DQ and 
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BCL-2. Selected genes and corresponding SNPs that passed quality control are listed in Supplementary 
Table 1. Illumina Infinium II 550 K SNP Chips and 610 Quad Chip (Illumina, Inc, San Diego, California) 
were used for genotyping in the CAMP study. SNPs of interest for replication were imputed based on 
1000 Genomes. GALA II subjects were genotyped using the Axiom® LAT1 array (World Array 4, 
Affymetrix, Santa Clara, CA) as described elsewhere [21]. Imputed data was obtained using the 
genotyped SNPs, first phasing the data using SHAPE-IT [22] followed by imputation using IMPUTE2 
[23] considering all populations from the 1000 Genomes Project Phase I v3 as a reference [24]. The 2 
SNPs selected SNPs for the current analyses were accurately imputed (info score of 0.96 and 0.99 for 
rs138335 and rs138337, respectively). In the PASS cohort, DNA samples of the participants were shipped 
to ARK-Genomics (The Roslin Institute, University of Edinburgh) for genome-wide genotyping on the 
Illumina Human OmniExpressExome-8 v1.0 chip (951,117 SNPs). After sample and SNP quality control 
measures, genotype data were phased using the software SHAPEIT v2.r644. Imputation of SNPs was then 
performed using IMPUTE v2.3.0. Statistical analyses were undertaken using PLINK v1.07 and/or 
SNPtest v2.4. 
  
 
Definition of outcome 
As indicators for asthma exacerbations we studied: 1) asthma-related hospital visits and, 2) course(s) of 
oral corticosteroid (OCS) use reported by parent or child.  The following outcome definitions as a 
measure for severe exacerbations were used:  
1) asthma-related hospital visits reported by the parent of a child:  
 BREATHE, and PAGES, PASS: asthma-related hospitalization in the past 6 months 
 PACMAN, GALA-II: asthma-related ED visits in the past 12 months 
 CAMP: asthma-related ED visits and hospitalizations in the first 12 months of the 
trial.  
2) burst(s) of OCS reported by the parent or child:  
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 BREATHE, and PAGES, PASS: in the past 6 months  
 PACMAN, GALA-II: in the past 12 months  
 CAMP: in the first 12 months of the trial  
 
 
Statistical analysis 
Logistic regression analysis was used to study the association between the SNPs and risk of exacerbations 
(OCS use or asthma-related hospital visits). Odds ratios (OR), 95% confidence intervals (CI) and p-values 
were calculated per study. The model was adjusted for age, gender and BTS treatment step. An additive 
genetic model was assumed. ORs were meta-analyzed assuming random effects with the inverse variance 
weighing method. I² was used to quantify between-study heterogeneity [205]. The Bonferroni-corrected 
p-value was set at p: 0.0007 (0.05/76)  False Discovery Rates (FDR) were calculated to estimate the 
proportion of false positives due to multiple testing [21].
 
 In addition, the risk estimates per genotype were 
calculated.  Statistical analysis was carried out using IBM SPSS 19.0 for Windows (SPSS, Inc, Chicago, 
Ill, USA) and PLINK [226]. Haplotype frequencies of the two ST13 SNPs were estimated using the EM 
algorithm implemented in the ‘haplo.stats’ package in R, Fforest plots were made with R and the ‘meta’ 
package [237].   
 
Functional annotation of associated SNPs 
Functional annotation of associated SNPs was carried out querying the Encyclopedia of DNA 
Elements (ENCODE) data with the online software HaploReg 
(http://www.broadinstitute.org/mammals/haploreg/haploreg.php)[28]. Additional search for evidence of 
associated loci being expression quantitative trait loci (eQTLs) was performed with using the Geuvadis 
Data Browser (http://www.ebi.ac.uk/Tools/geuvadis-das)[29].  
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Results 
Characteristics of the study populations 
Data were available for 820 children and young adults of the BREATHE cohort, 391 children and 
adolescents of PAGES and,  357 children of the PACMAN cohort and 172 children of CAMP (Table 1). 
Most patients were on BTS treatment step 2 (as-needed short-acting beta-agonist use combined with 
regular low dose ICS). Compared to the other studies, the participants in the PACMAN cohort reported 
the lowest rates of asthma-related hospital visits (6.2%) and OCS usage (6.2%) in the past year.  
Furthermore, data from three additional studies were available for the replication phase; 172 non-Hispanic 
white children of the CAMP trial, 391 children of the PASS cohort and 745 Latino children and young 
adults of the GALA II study (Table 2).  
 
Discovery phase: Associations with severe exacerbations in BREATHE, PAGES and PACMAN 
In a meta-analysis of the three North-European cohorts BREATHE, PAGES and PACMAN, we found 
two out of the 38 SNPs to be associated with an altered risk of severe exacerbations as defined by asthma-
related hospital visits. ST13 SNP rs138335 increased the risk of asthma-related hospital visits (OR=1.35 
per G allele; 95%CI: 1.07-1.7069, p=0.01, FDR: 25%) (Figure 1). Rs138337 in the same gene, had a 
similar comparable effect on the risk of  asthma-related hospital visits (OR: 1.36 per G allele, 95%CI: 
1.11-1.676, p=0.003, FDR: 11%) (Figure 2Table 2). In addition, rs138335 was also associated with  an 
increased risk of OCS use (OR: 1.33 per G allele; 95%CI: 1.11-1.5960, p=0.002, FDR: 11%) (Figure 3). 
In Supplementary tables 2 and 3 show the summary effect estimates of all investigated SNPs are shown.  
 
 
Replication phase: ST13 in a fourth independent asthma populationthe CAMP, GALA II and PASS 
cohorts   
In order to assess the robustness of findings we studied rs138337 and rs138335 in a fourth three 
additional independent study populations; the North-American CAMP study (n=172 non-Hispanic white 
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asthmatic children), the PASS cohort (n=391 North-European asthmatic children) and the GALA II study 
(n=745 Latino asthmatic children). In a meta-analysis of the three cohorts, none of the ST13 SNPs was 
significantly associated with severe exacerbations (Figure 1-3).  When investigating the study populations 
independently, we observed a trend (p=0.06) in the North-European PASS cohort suggesting that carrying 
a G-allele at rs138335 increased the risk of asthma-related hospital visits in this study population (OR: 
1.42, 95%CI: 0.97-2.07; Figure 1), whereas the other 2 cohorts did not significantly contribute.  
 
Meta-analysis of the six study populations  
In the meta-analysis of all six study populations,  ST13 rs138335 remains associated with asthma-related 
hospital-visits (OR per increase in G-allele: 1.22, 95%CI: 1.04-1.43, p=0.013) and OCS usage (OR per 
increase in G-allele: 1.22, 95%CI: 1.08-1.39, p=0.0017). The effect estimates in the different cohorts 
largely pointed in the same direction for both outcomes, yet these associations did not pass the 
Bonferroni-corrected significance threshold of 0.0007.   
 
Functional annotation of associated SNPs 
The associated SNPs rs138337 and rs138335 are eQTLs in lymphoblastoid cell lines from Europeans 
(p=5.8x10
-70
 and p=1.9x10
-36
, respectively). In addition, the SNP rs138335 is in strong linkage 
disequilibrium (LD, r
2
=0.95) with another SNP (rs138349) that is located in a promoter histone mark, an 
enhancer histone mark, a DNase I hypersensitive site, and acts as a binding site for an enhancer binding 
protein and transcription factors. Furthermore, the SNP rs138335 is in high LD (r
2
=0.86) with the SNP 
rs2899341, which is located in an enhancer histone mark and in a DNase I hypersensitive site. 
 
Genotyping data for ST13 were available for 172 asthmatic steroid-treated non-Hispanic white children. 
In this clinical trial population, the two SNPs in ST13 were not significantly associated with risk of severe 
exacerbation, but this might be due to a lack of power considering the small study population. In a second 
meta-analysis including all four studies (Table 2), both SNPS increased the risk of asthma related hospital 
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visits. For rs138337 the OR per G-allele for asthma-related hospital visits was 1.31 (95%CI: 1.08-1.59, 
p=0.007, FDR: 19%) and for rs138335 the OR per G-allele was 1.28 (95%CI: 1.04-1.59, p=0.02, FDR: 
36%). Furthermore, both SNPs were associated with an increased risk of OCS usage; the OR per G-allele 
was 1.18 for rs138337 (95%CI: 1.01-1.38, p=0.03, FDR: 41%) and 1.30 per G allele for rs138335 
(95%CI: 1.09-1.54, p=0.003, FDR: 10%). Forest plots are shown in Figure 1.  
To assess the risk stratified per genotype we additionally performed a genotypic analysis whereby 
rs138335 CC and rs138337 AA were used as reference groups (Table 3). In a meta-analysis the highest 
risk estimates were found for carriers of rs138335 GG and risk of OCS usage (OR rs138335 GG 
compared to CC: 1.98, p=0.002) and carriers of rs138337 GG and risk of asthma-related hospital visits 
(OR rs138337 GG compared to rs138337 AA: 1.75, p=0.007).  
 
ST13 haplotypes are associated with asthma-related hospital visits 
Based on the available genotype information, three haplotypes were estimated to have a frequency >2% 
(Table 4).  The most common haplotype was rs138335-G/rs138337-G. There was a significant association 
between ST13 haplotype and asthma-related hospital visits, whereby compared to the most common 
haplotype,  the haplotype without risk alleles (rs138335-C/rs138337-A) conferred the most protection 
(OR: 0.96, 95%CI: 0.94-0.99) (Table 5). 
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Discussion 
In a meta-analysis of three independent North-European studies we identified ST13 as a novel risk gene 
for the occurrence of asthma exacerbations despite inhaled corticosteroid treatment in asthmatic children 
and young adults. For rs138335 the risk of exacerbations was increased with each substitution of the 
minor allele for the major allele variant. For rs138337, oppositely, the minor allele variant was found to 
be associated with an increased risk of exacerbations. The two SNPs were in moderate LD (r
2
=0.47) in 
our study.  None of the other investigated genes could be linked to an increased risk of severe 
exacerbations.   
 
SNPs rs138335 and rs138337 both lie in the non-coding intronic regions of the ST13 gene, but may still 
affect gene expression, splicing or be in high LD with a variant that has functional consequences. 
However, there were no expression quantitative trait loci (eQTL) data available for both SNPs 
(http://www.ncbi.nlm.nih.gov/gap/PheGenI), nor could we identify a coding SNP in high LD with 
rs138335 and/or rs138337 (www.ensembl.org) our in silico functional evaluation revealed a functional 
role for these two SNPs as eQTLs and also for SNPs in high LD with them. ST13 encodes a co-chaperone 
protein (Hsp70 interacting protein; hip) of the steroid-receptor complex and is involved in the functional 
maturation of the corticosteroid receptor, but the mechanism by which it does so remains to be elucidated 
[2430]. STIP1 (coding for another co-chaperone protein in the GR receptor complex, namely 
Hsp70/Hsp90-organizing protein: hop) has previously been associated with lung function and lung 
function improvement in 382 asthmatic patients treated with ICS [10]. At the time of SNP selection, 
STIP1 was not included in our study. Hip (encoded by ST13) and hop (encoded by STIP1) are thought to 
function in a cooperative manner in GR maturation [3024], building evidence that alterations in the 
expression or folding of these co-chaperones may influence the binding of corticosteroids to the receptor 
or downstream signaling and therefore, ICS responsiveness. Functional studies are necessary to support 
our hypothesis.    
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A number of limitations need to be noted regarding the present study. Two SNPs in ST13 were associated 
with both outcomes of exacerbations in the meta-analysis of all four six cohorts, but did not pass the 
Bonferroni-corrected significance threshold. Therefore, we cannot exclude that our findings are false-
positives. Even though we were able to analyze a large study population (including 2876 asthmatic 
children and young adults), a post-hoc power analysis showed we were underpowered to identify a 
significant association with an OR<1.5 for asthma-related hospital visits and OR<1.4 for OCS use. This 
underlines the need for large-scale international collaboration in this field [31]. the expected proportions 
of false discoveries (FDR rates) due to multiple testing ranged for both SNPs and the two outcomes in the 
second meta-analysis between 10-41%. We used FDR rates as a measure to correct for multiple testing, 
Bonferroni corrected p-values might be too conservative in candidate-gene approaches were SNP are in 
background LD. Although, the FDR rates are > 5% (which is often used as cut-of value), the biological 
function of ST13 and the previous identified association of STIP1 with ICS response in asthmatic patients 
[10], strongly suggest that the identified association is not a false discovery. Furthermore, the SNPs were 
tested in 4 distinct study populations, and the effect estimates for both measures of severe exacerbations 
pointed in the same direction in the three largest study populations included in our study.  
 
The study populations we studied varied in age and severity of asthma symptoms, . This probably due to 
the design of the studies.; tThe PACMAN population is recruited in community pharmacies, whereby 
most participants had well-controlled symptoms [3225], while patients in PAGES, BREATHE and 
CAMP were recruited through primary and secondary care. PASS participants were recruited through 
secondary care based on clinical concern about adrenal suppression, while participants in GALA II were 
recruited using a combination of community and clinic-based recruitment.   In addition, differences in 
health system and prescription behavior between the two different countries might also play a role [3326]. 
Notwithstanding these differences, statistical heterogeneity (I
2
) was limited for ST13 in the meta-analysis. 
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Our study was also limited due to the selection of tagging SNPs with a MAF ≥ 0.20. Due to the sample 
size, we We could not investigatestudy rare variants, which might have had larger effects. However, our 
study population was too small to study rare variants.  Furthermore, the incorporation of common variants 
with smaller effects in clinical risk models might be valuable for a larger group of the asthma patient 
population.  
 
In summary, variations in a novel risk gene ST13 are seem to be associated with an increased risk of 
severe exacerbations in children and young adults despite their use of ICS treatment. Although the effect 
sizes are modest, these results may provide insights into the biological mechanisms that underlie severe 
exacerbations in asthmatic patients treated with steroids. Heterogeneity in corticosteroid response is 
probably caused by a complex interaction of genetic and environmental factors. Including ST13 risk status 
in a multidimensional model with other genetic and non-genetic risk factors (e.g: exposure to tobacco 
smoke [3427] or vitamin D levels [3528]) might explain a larger part of the observed variability inmay 
reveal more precisely interindividual ICS treatment responses.  
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Table 1. Baseline characteristics study population  in the discovery phase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BTS, British Thoracic Society, * PACMAN cohort: preceding 12 months, BREATHE/PAGES: preceding 6 months.  
§ data not available for all individuals; (number of individuals / number of individuals with data available). For BREATHE, the individual with missing hospital 
data is different from the individual with missing OCS data.  
± Children within the PACMAN cohort were selected between the age of 4-12. However, the child might have been 13 at the moment of the study visit.  
 BREATHE 
(n=820) 
PAGES (n=391) PACMAN (n=357) 
Child characteristics    
Age, mean (SD)range (yrs) 9.8 (4.02-22) 9.0 (2-163.8) 8.7 (4-132.3)± 
Male gender, % 61.2 55.8 61.1 
Asthma exacerbations in preceding 12 months / 6 months    
Asthma-related ED visit/hospital admission*, % 19.0 (156/819)§ 15.5  6.2 (22/356)§ 
Oral steroid use*, % 31.6 (259/819)§ 43.2 6.2 
BTS treatment step    
2, % 65.9 48.8 71.7 
3, % 18.3 42.2 23.0 
4, %  15.9 9.0 5.3 
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¶ CAMP is Randomized Clinical Trial of mild-to moderate asthmatics. All children were on 200 µg of budesonide (ICS) plus SABA as needed.  
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Table 2. Baseline characteristics study population in the replication phase 
 
¶ CAMP is Randomized Clinical Trial of mild-to moderate asthmatics. All children were on 200 µg of budesonide 
(ICS) plus SABA as needed.  
# Prospective trial; children were 5-13 years at the start of the trial.  
 
 
 
 CAMP (n=172) PASS (n=391)  GALA II  
(n=745) 
Child characteristics    
Age, range (yrs) 8.8 (5-13)# 11.1 (5-18) 12.1 (8-21) 
Male gender, % 55.2 55.8 56.8 
Asthma exacerbations in preceding 12 months / 6 
months 
   
Asthma-related ED visit/hospital admission*, % 13.4  75.4 42.4 (313/739) 
Oral steroid use*, % 47.1  51.9 41.6 (310/745) 
BTS treatment step    
2, % ¶ 7.7 41.1 
3, % - 33.0 43.6 
4, %  - 58.8 15.3 
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Figure 1. Forest plot for the association between ST13 rs138335 and asthma-related hospital visits. Odds ratios 
(OR) and corresponding 95%CI per increase in G-allele, controlling for age, sex and treatment step.  
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Figure 2. Forest plot for the association between ST13 rs138337 and asthma-related hospital visits. Odds ratios 
(OR) and corresponding 95%CI per increase in G-allele, controlling for age, sex and treatment step.  
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Figure 3. Forest plot for the association between ST13 rs138335 and OCS usage. Odds ratios (OR) and 
corresponding 95%CI per increase in G-allele, controlling for age, sex and treatment step.  
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Supplementary Table 1. Selected genes with corresponding SNPs that passed quality control  
Gene SNPs Description  Function  
NR3C1 rs4607376 
rs4912912 
rs7701443 
rs9324924 
rs2963155 
rs4912905 
rs6865292 
rs17209258 
rs6196 
Nuclear receptor subfamily 3 
group C member 1 
Glucocorticosteroid receptor (GR) [1] 
KFBP4 rs1981655 
rs11833878 
 
FK506 binding protein 4 Chaperone, binds dynein upon ligand binding of 
GR [2] 
ST13 rs138335 
rs138337 
 
suppression of tumorigenicity 
13 
Co-chaperone, mediates assembly chaperone GR 
complex [3] 
CREBBP rs130021 
rs11076787 
rs886528 
rs2526689 
cAMP-response element 
binding protein  
Transcriptional co-activator  [4] 
TBP rs2235506 
rs3800235 
 
TATA box binding protein Transcriptional co-activator  [5] 
NCOA3 rs2425941 
rs6066394 
rs2143491 
rs6018600 
rs11700063 
nuclear receptor coactivator 3 Transcriptional co-activator, acylates histones.  
[6] 
SMAD3 rs744910 Mothers against 
decapentaplegic homolog 3 
Transcription factor, regulated by GR. Associated 
with asthma susceptibility [7] 
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SERPINA6 rs1956179 
rs7158343  
rs10498639 
rs1998056 
rs2281518 
rs2281519 
rs2281520 
rs11629171  
Corticosteroid-binding globulin Protein involved in plasma corticosteroid-binding 
globulin activity [8] 
ARG1 rs2781667 Arginase, liver Arginase (enzyme), thought to be involved in 
asthma pathogenesis through effects on 
nitrosative stress. Associated with bronchodilator 
response [9] 
17q21 locus rs7216389 
 
Involved in expression of 
orosomucoid - like protein 3 
Locus thought to be associated with asthma 
susceptibility and therapy response [10-13] 
PDE4D rs1544791 
rs1588265 
phosphodiesterase 4D Degrades cAMP. Thought to be associated with 
asthma susceptibility [14] 
IL2RB rs2284033 Interleukin 2 receptor, beta Binds interleukin 2, involved in T cell mediated 
immune responses. Associated with asthma 
susceptibility [7] 
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Supplementary Table 2. Summary effect estimates of SNPs in candidate genes and asthma-related hospital 
visits in a meta-analysis of BREATHE, PAGES & PACMAN
1 
SNP CHR BP Gene Effect 
allele 
p-value OR I (%) q-value 
rs138337 22 39560999 ST13 G 0.003 1.36 0 0.11 
rs138335 22 39557032 ST13 C 0.010 0.74 0 0.25 
rs6066394 20 45643560 NCOA3 T 0.099 1.21 0 0.92 
rs6018600 20 45691984 NCOA3 A 0.116 1.18 0 0.92 
rs1956179 14 93855495 SERPINA6 G 0.129 1.18 0 0.92 
rs2963155 5 142736197 NR3C1 G 0.207 0.86 0 0.92 
rs4607376 5 142776725 NR3C1 A 0.219 1.13 0 0.92 
rs7216389 17 35323475 17q21locus§ C 0.266 0.81 59 0.92 
rs2425941 20 45590796 NCOA3 T 0.269 0.89 0 0.92 
rs17209258 5 142653590 NR3C1 G 0.273 1.25 55 0.92 
rs2526689 16 3857884 CREBBP G 0.337 0.90 0 0.92 
rs2281518 14 93858870 SERPINA6 C 0.342 1.13 0 0.92 
rs2281520 14 93846140 SERPINA6 C 0.358 0.88 10 0.92 
rs10498639 14 93845279 SERPINA6 A 0.400 1.09 0 0.92 
rs3800235 6 170718978 TBP C 0.410 1.10 0 0.92 
rs11700063 20 45586555 NCOA3 A 0.427 0.86 44 0.92 
rs1588265 5 59405551 PDE4D G 0.438 0.88 44 0.92 
rs1998056 14 93859248 SERPINA6 G 0.448 0.92 0 0.92 
rs2281519 14 93846385 SERPINA6 T 0.484 1.08 0 0.92 
rs4912912 5 142787343 NR3C1 C 0.516 0.93 0 0.92 
rs1544791 5 59474839 PDE4D A 0.531 0.90 44 0.92 
rs886528 16 3751557 CREBBP C 0.566 1.14 70 0.92 
rs130021 16 3772472 CREBBP G 0.606 0.89 67 0.92 
rs4912905 5 142710569 NR3C1 C 0.625 0.94 0 0.92 
rs6865292 5 142773183 NR3C1 C 0.662 1.05 0 0.92 
rs7701443 5 142772843 NR3C1 G 0.699 0.96 0 0.92 
rs2235506 6 170720811 TBP C 0.721 0.96 0 0.92 
rs11833878 12 2780498 KFBP4 G 0.738 0.95 0 0.92 
rs744910 15 65233839 SMAD3 A 0.741 0.96 28 0.92 
rs2143491 20 45662074 NCOA3 A 0.747 0.97 0 0.92 
rs6196 5 142641683 NR3C1 G 0.748 0.96 0 0.92 
rs9324924 5 142772677 NR3C1 T 0.762 0.94 55 0.92 
rs11629171 14 93843203 SERPINA6 T 0.867 1.02 21 0.96 
rs2284033 22 35863980 IL2RB A 0.875 1.02 0 0.96 
rs11076787 16 3792777 CREBBP T 0.901 0.98 0 0.96 
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* OR adjusted for age, gender and BTS treatment step, 
1
PACMAN: asthma-related ER visits in the preceding 12 
months, BREATHE/PAGES: asthma-related hospitalization in the preceding 6 months. § locus involved in the 
regulation of several genes. OR= Odds Ratio assuming random effect model, I= heterogeneity (%).BP: base pair. 
Positions were based on NCBI Build 36. 
rs1981655 12 2777987 KFBP4 A 0.926 1.03 0 0.96 
rs2781667 6 131936837 ARG1 T 0.950 1.01 0 0.96 
rs7158343 14 93852906 SERPINA6 G 0.963 1.01 0 0.96 
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Supplementary Table 3. Summary effect estimates of SNPs in candidate genes and oral corticosteroids use in 
the previous year in a meta-analysis of BREATHE, PAGES & PACMAN
1 
SNP CHR BP Gene Effect 
allele 
p-value OR I (%) q-value 
rs138335 22 39557032 ST13 C 0.002 0.75 0 0.11 
rs138337 22 39560999 ST13 G 0.099 1.18 20 0.92 
rs7216389 17 35323475 17q21 locus§ C 0.102 0.80 49 0.92 
rs6196 5 142641683 NR3C1 G 0.169 1.24 40 0.92 
rs2963155 5 142736197 NR3C1 G 0.179 1.20 39 0.92 
rs744910 15 65233839 SMAD3 A 0.188 0.89 6 0.92 
rs6018600 20 45691984 NCOA3 A 0.215 1.11 0 0.92 
rs4912912 5 142787343 NR3C1 C 0.224 0.90 0 0.92 
rs7158343 14 93852906 SERPINA6 G 0.262 1.12 5 0.92 
rs2284033 22 35863980 IL2RB A 0.292 1.15 47 0.92 
rs11629171 14 93843203 SERPINA6 T 0.308 0.89 17 0.92 
rs1998056 14 93859248 SERPINA6 G 0.317 0.92 0 0.92 
rs11833878 12 2780498 KFBP4 G 0.326 1.19 42 0.92 
rs6865292 5 142773183 NR3C1 C 0.348 1.11 25 0.92 
rs1981655 12 2777987 KFBP4 A 0.357 1.23 0 0.92 
rs10498639 14 93845279 SERPINA6 A 0.410 0.89 56 0.92 
rs2235506 6 170720811 TBP C 0.458 1.07 0 0.92 
rs9324924 5 142772677 NR3C1 T 0.463 1.07 0 0.92 
rs7701443 5 142772843 NR3C1 G 0.466 0.94 0 0.92 
rs4607376 5 142776725 NR3C1 A 0.543 1.05 0 0.92 
rs130021 16 3772472 CREBBP G 0.554 0.95 0 0.92 
rs11700063 20 45586555 NCOA3 A 0.620 1.05 0 0.92 
rs6066394 20 45643560 NCOA3 T 0.642 1.06 30 0.92 
rs1544791 5 59474839 PDE4D A 0.646 0.94 48 0.92 
rs2143491 20 45662074 NCOA3 A 0.654 1.04 0 0.92 
rs2281519 14 93846385 SERPINA6 T 0.686 0.96 0 0.92 
rs2281520 14 93846140 SERPINA6 C 0.693 1.06 43 0.92 
rs2526689 16 3857884 CREBBP G 0.710 0.97 0 0.92 
rs17209258 5 142653590 NR3C1 G 0.714 0.96 0 0.92 
rs1588265 5 59405551 PDE4D G 0.749 0.95 64 0.92 
rs2281518 14 93858870 SERPINA6 C 0.750 1.04 23 0.92 
rs11076787 16 3792777 CREBBP T 0.809 1.03 0 0.96 
rs2425941 20 45590796 NCOA3 T 0.823 0.98 0 0.96 
rs2781667 6 131936837 ARG1 T 0.864 1.02 15 0.96 
rs1956179 14 93855495 SERPINA6 G 0.872 0.98 31 0.96 
rs3800235 6 170718978 TBP C 0.912 1.01 0 0.96 
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rs886528 16 3751557 CREBBP C 0.931 1.01 0 0.96 
rs4912905 5 142710569 NR3C1 C 0.950 0.99 12 0.96 
 
OR adjusted for age, gender and BTS treatment step, 
1
PACMAN: OCS use in the past 12 months, 
BREATHE/PAGES: OCS use in the past 6 months.  § locus involved in the regulation of several genes. OR= Odds 
Ratio assuming random effect model, I= heterogeneity (%). BP: base pair. Positions were based on NCBI Build 36.  
 
 
 
Page 37 of 42 Clinical & Experimental Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Supplementary references  
1. Bray P, Cotton R. Variations of the human glucocorticoid receptor gene (NR3C1): Pathological and in vitro 
mutations and polymorphisms. Hum Mut 2003;21:557-68. 
2. Wochnik GM, Ruegg J, Abel GA, Schmidt U, Holsboer F, Rein T. FK506-binding proteins 51 and 52 
differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian 
cells. J Biol Chem 2005;280:4609-16. 
3. Nelson GM, Prapapanich V, Carrigan PE, Roberts PJ, Riggs DL, Smith DF. The Heat Shock Protein 70 
Cochaperone Hip Enhances Functional Maturation of Glucocorticoid Receptor. Mol Endocrinol 2004;18:1620-30. 
4. Kino T, Nordeen SK, Chrousos GP. Conditional modulation of glucocorticoid receptor activities by CREB-
binding protein (CBP) and p300. J Steroid Biochem Mol Biol 1999;70:15-25. 
5. Khan SH, Ling J, Kumar R. TBP binding-induced folding of the glucocorticoid receptor AF1 domain facilitates 
its interaction with steroid receptor coactivator-1. PLoS One 2011;6:e21939. 
6. Yu C, York B, Wang S, Feng Q, Xu J, O'Malley BW. An essential function of the SRC-3 coactivator in 
suppression of cytokine mRNA translation and inflammatory response. Mol Cell 2007;25:765-78. 
7. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, 
Cookson WOCM. A Large-Scale, Consortium-Based Genomewide Association Study of Asthma. N Engl J Med 
2010;363:1211-21. 
8. Lin HY, Underhill C, Lei JH, Helander-Claesson A, Lee HY, Gardill BR, Muller YA, Wang H, Hammond GL. 
High frequency of SERPINA6 polymorphisms that reduce plasma corticosteroid-binding globulin activity in 
Chinese subjects. J Clin Endocrinol Metab 2012;97:E678-86. 
9. Litonjua AA, Lasky-Su J, Schneiter K, Tantisira KG, Lazarus R, Klanderman B, Lima JJ, Irvin CG, Peters SP, 
Hanrahan JP, Liggett SB, Hawkins GA, Meyers DA, Bleecker ER, Lange C, Weiss ST. ARG1 is a novel 
bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med 
2008;178:688-94. 
10. Halapi E, Gudbjartsson DF, Jonsdottir GM, Bjornsdottir US, Thorleifsson G, Helgadottir H, Williams C, 
Koppelman GH, Heinzmann A, Boezen HM, Jonasdottir A, Blondal T, Gudjonsson SA, Jonasdottir A, Thorlacius T, 
Henry AP, Altmueller J, Krueger M, Shin HD, Uh S, Cheong HS, Jonsdottir B, Ludviksson BR, Ludviksdottir D, 
Gislason D, Park C, Deichmann K, Thompson PJ, Wjst M, Hall IP, Postma DS, Gislason T, Kong A, Jonsdottir I, 
Thorsteinsdottir U, Stefansson K. A sequence variant on 17q21 is associated with age at onset and severity of 
asthma. Eur J Hum Genet 2010;18:902-8. 
11. Bisgaard H, Bønnelykke K, Sleiman PMA, Brasholt M, Chawes B, Kreiner-Møller E, Stage M, Kim C, 
Tavendale R, Baty F, Pipper CB, Palmer CNA, Hakonarsson H. Chromosome 17q21 gene variants are associated 
with asthma and exacerbations but not atopy in early childhood. Am J Respir Crit Care Med 2009;179:179-85. 
12. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, Depner M, von Berg A, Bufe A, Rietschel E, 
Heinzmann A, Simma B, Frischer T, Willis-Owen SA, Wong KC, Illig T, Vogelberg C, Weiland SK, von Mutius E, 
Abecasis GR, Farrall M, Gut IG, Lathrop GM, Cookson WO. Genetic variants regulating ORMDL3 expression 
contribute to the risk of childhood asthma. Nature 2007;448:470-3. 
13. Tavendale R, Macgregor DF, Mukhopadhyay S, Palmer CNA. A polymorphism controlling ORMDL3 
expression is associated with asthma that is poorly controlled by current medications. J Allergy Clin Immunol 
2008;121:860-3. 
14. Himes BE, Hunninghake GM, Baurley JW, Rafaels NM, Sleiman P, Strachan DP, Wilk JB, Willis-Owen SA, 
Klanderman B, Lasky-Su J, Lazarus R, Murphy AJ, Soto-Quiros ME, Avila L, Beaty T, Mathias RA, Ruczinski I, 
Barnes KC, Celedon JC, Cookson WO, Gauderman WJ, Gilliland FD, Hakonarson H, Lange C, Moffatt MF, 
O'Connor GT, Raby BA, Silverman EK, Weiss ST. Genome-wide association analysis identifies PDE4D as an 
asthma-susceptibility gene. Am J Hum Genet 2009;84:581-93. 
 
Page 38 of 42Clinical & Experimental Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Dear Prof. dr. Wardlaw 
 
We would like to thank you and the expert reviewer for the comments and suggestions regarding our 
manuscript. We have rigorously revised the manuscript, added new figures and tables, and have marked all 
changes by underlining in the revised manuscript.  
 
In the revised manuscript we have added two new cohorts (PASS and GALA II), thereby almost doubling 
our study population (from 1740 to 2876 study subjects). The final meta-analysis includes 6 cohorts and 
indicates a strong collaborative effort in the field of pharmacogenetics of pediatric asthma. Furthermore, we 
have put more focus on the discovery and the replication phase in order to increase the readability of the 
paper.  
 
In this letter we would like to respond to the remarks and suggestions of the reviewer point by point:  
 
 
Major comments: 
 
Power – The power of the study was not stated, although FDR rates were analysed. The 95% CIs 
show a wide range of effect, with some ORs close to 1, so limited power is certainly a consideration 
in this study. It is recognized that there are few cohorts available like these, for ICS 
pharmacogenomics studies, so the authors have done well to include all of these studies.  
 
We agree with the reviewer that limited power is an issue in this study, and in the revised 
manuscript we have put a lot of effort in including additional cohorts to increase the study sample 
size. We have added two new cohorts to our study, increasing our study population from 1740 to 
2876 individuals. Nevertheless, the power in the discovery phase remains limited. We have now 
addressed this in our discussion at p.18: 
 
“Even though we were able to analyze a large study population (including 2876 asthmatic children 
and young adults), a post-hoc power analysis showed we were underpowered to identify a 
significant association with an OR<1.5 for asthma-related hospital visits and OR<1.4 for OCS use. 
This underlies the need for large-scale international collaboration in this field.[31]”  
 
 
2 meta-analyses – The authors have employed the technique of 2 meta-analyses, to provide an 
approach to replication of genetic associations. Whilst the CAMP cohort is well-characterised and 
important to include, the additional of approximately another 10% of participants to the total 
number does not seem to add substantially to the replication. i.e. a small addition of participants 
may not significantly alter the effect sizes of the first meta-analysis. It may be better just to include 
all 4 studies in one combined analysis.  
 
In the revised manuscript we have added two additional replication cohorts (PASS and GALA II). 
We have stratified our analyses in a discovery phase (analyzing PACMAN, BREATHE and 
PAGES) and a replication phase, in which we have analyzed the most significant SNPs from the 
discovery phase in CAMP, PASS and GALA II. Lastly, we have performed a meta-analysis of all 
six studies. Rs138335 remains associated with an increased risk of exacerbations (at nominal level) 
in this final meta-analyses. This is now depicted in figures 1 and 3: 
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Figure 1. Forest plot for the association between ST13 rs138335 and asthma-related hospital visits. Odds ratios 
(OR) and corresponding 95%CI per increase in G-allele, controlling for age, sex and treatment step.  
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Figure 3. Forest plot for the association between ST13 rs138335 and OCS usage. Odds ratios (OR) and 
corresponding 95%CI per increase in G-allele, controlling for age, sex and treatment step.  
 
 
 
 
Other SNPs – In the list of candidate SNPs, GLCCI1 SNPs (from a previous large study of ICS 
respons) was not included. I presume this is because the GLCCI1 SNPs had already been studied in 
the CAMP cohort, and are not a direct member of the GR complex. 
 
GLCCI1 was not included in this manuscript. At the time of the discovery phase the relation 
between treatment response and GLCCI1 SNPs (rs37972/rs37972) had not been published and was 
not included in the study protocol. However, since then GLCCI1 rs37972 has been analyzed 
separately in BREATHE, PAGES and PACMAN, as a replication study of the CAMP results. That 
paper has been published recently in Pharmacogenomics:  
 
Vijverberg et al. Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma 
populations with a reported use of inhaled corticosteroids. Pharmacogenomics 2014 15(6): 799-806 
doi 10.2217/pgs.14.37.  
 
 
Dose-response – Even though this study is relatively underpowered, and involves a range of ages of 
children and young adults,  
 
Unfortunately, dosages of the inhaled and oral corticosteroids have not been reported in all studies. 
Furthermore, the children included in CAMP have all been treated with the same amount of ICS 
due to the clinical trial set up. Therefore, we were unable to perform a dose-response analysis.  
 
Variability – Can the authors estimate how much of the steroid-response variability is contributed to 
by these SNPs? 
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The estimation of the ST13 SNPs on the steroid-response variability is very complicated. Especially 
since we were unable to perform a dose-response analysis, it is difficult to quantify the contribution 
of the SNPs on the variability in response. Based on the limited effect sizes of the SNPs we assume 
that they will have a small effect on the variability of response. Nevertheless, this effect might still 
be valuable to understand the pathobiological background of ICS response in asthmatic children and 
young adults.  
 
Minor comments: 
 
Discussion paragraph 3 –  
‘We used FDR rates as a measure to correct for multiple testing, Bonferroni corrected 
p-values might be too conservative in candidate-gene approaches were SNP are in 
background LD’ 
Should this read ‘where SNPs are in….’ 
 
In the revised manuscript this sentence has been removed.  
 
Table 1 – The actual age range of the participants would be useful to include in this demographics 
table.  
 
We have added the age range in table 1 (baseline characteristics of the studies included in the 
discovery phase), and included this in our newly added table 2 (baseline characteristics of the 
studies included in the replication phase): 
 
Table 1. Baseline characteristics of the study population in the discovery phase 
 
 BREATHE 
(n=820) 
PAGES (n=391) PACMAN 
(n=357) 
Child characteristics    
Age, range (yrs) 9.8 (2-22) 9.0 (2-16) 8.7 (4-13)± 
Male gender, % 61.2 55.8 61.1 
Asthma exacerbations in preceding 12 months / 6 
months 
   
Asthma-related ED visit/hospital admission*, % 19.0 
(156/819)§ 
15.5  6.2 (22/356)§ 
Oral steroid use*, % 31.6 
(259/819)§ 
43.2 6.2 
BTS treatment step    
2, % 65.9 48.8 71.7 
3, % 18.3 42.2 23.0 
4, %  15.9 9.0 5.3 
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BTS, British Thoracic Society, * PACMAN cohort: preceding 12 months, BREATHE/PAGES: preceding 6 months.  
§ data not available for all individuals; (number of individuals / number of individuals with data available) 
± children within the PACMAN cohort were selected between the age of 4-12. However, the child might have been 13 
at the moment of the study visit.  
 
 
Table 2. Baseline characteristics study population in the replication phase 
 
 
¶ CAMP is Randomized Clinical Trial of mild-to moderate asthmatics. All children were on 200 µg of budesonide 
(ICS) plus SABA as needed.  
# Prospective trial; children were 5-13 years at the start of the trial.  
 
 CAMP (n=172) PASS (n=391)  GALA II  
(n=745) 
Child characteristics    
Age, range (yrs) 8.8 (5-13)# 11.1 (5-18) 12.1 (8-21) 
Male gender, % 55.2 55.8 56.8 
Asthma exacerbations in preceding 12 months / 6 
months 
   
Asthma-related ED visit/hospital admission*, % 13.4  75.4 42.4 (313/739) 
Oral steroid use*, % 47.1  51.9 41.6 (310/745) 
BTS treatment step    
2, % ¶ 7.7 41.1 
3, % - 33.0 43.6 
4, %  - 58.8 15.3 
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